Medicinal Products


Generic drug of the therapeutic class: Infectiology - Parasitology
active ingredients: Sulfadiazine
laboratory: Bouchara-Recordati

Box of 20
All forms


Reserved for adults and children over 10 kg (about 1 year).

They result from the antibacterial and antiparasitic activity of sulfadiazine and its pharmacokinetic characteristics. They take into account both the clinical studies of this drug and its place in the range of anti-infective products currently available.

They are limited to infections due to germs defined as sensitive:

· Treatment of toxoplasmosis, particularly in immunocompromised patients, usually in combination with pyrimethamine.

· Prevention of relapses of visceral toxoplasmosis of the immunocompromised.

· Treatment of nocardiosis.

Dosage ADIAZINE 500 mg Tablet Box of 20

Oral way.

In the treatment of toxoplasmosis and nocardiosis, the dosage is:

· In adults: 8 to 12 tablets a day,

· In children over 10 kg (approximately 1 year): 150 mg / kg daily.

For the prevention of relapse of visceral toxoplasmosis of the adult immunodepressed, the usual dosage is 2 g per day, in combination with pyrimethamine.

The dosage is divided into 4 to 6 doses.

For children under 6, tablets should be crushed. The tablets being slightly bitter, it is better to mix them with a food (fruit juice, yogurt, puree ...).

Against indications

This medicine MUST NOT BE USED in the following situations:

Hypersensitivity to sulfadiazine or sulfonamides or to any of the excipients.

· In patients with wheat allergy (other than celiac disease),

· During breastfeeding if the newborn is less than one month old,

· In case of G6PD deficiency, including in the breastfed child: risk of haemolysis,

· In case of severe hepatic insufficiency and severe renal insufficiency.

Breastfeeding is not recommended during treatment with sulfadiazine (see section Pregnancy and breastfeeding pregnancy and lactation).

Adiazine side effects

· Gastrointestinal intolerance: nausea, gastralgia

· Hematologic manifestations: thrombocytopenia, immuno-allergic haemolytic anemia, neutropenia, exceptionally medullary aplasia.

· Risk of acute haemolysis in subjects with G6PD deficiency.

· Skin manifestations: rash, urticaria; some cases of unpredictable and sometimes fatal epidermal necrolysis (Lyell syndrome) have been reported.

· Renal and urinary manifestations: urinary tract lithiasis that may manifest as renal colic, hematuria or acute renal failure. This risk can be prevented by maintaining an abundant alkaline diuresis (see Warnings and precautions for use ).

· Liver manifestations: Increased transaminases and hepatitis.

Popular Posts

Category Medicinal Products, Next Article